A Phase 2 interventional study of Bomedemstat in Thrombocythemia, Essential and Primary Myelofibrosis, sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA). Completed at 19 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-22.
Sponsored by Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 149 studies in Thrombocythemia, Essential with a site in United States — 18 open to participants now, 32 under way, 6 of them phase 3. Thrombocythemia, Essential · United States.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, this one is the 35th largest by enrollment of the 120 interventional ones that give a count, is one of 3 that started in 2021, is one of 49 in phase 2, and was the 131st registered.
229 studies on the registry are indexed under Thrombocythemia, Essential; 38 are open to participants now.
Browse Thrombocythemia, Essential studies →18 of the 149 studies in Thrombocythemia, Essential with a site in United States are open now. Recruiting first, the newest first:
Incyte Corporation · Sites in United States, Australia, Austria and 19 more countries
Ages 18+
Damora Therapeutics · Sites in United States, Australia
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 2 more countries
Ages 18+
MPN Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Thrombocythemia, Essential studies recruiting now, 30 (88%) set no upper age limit and 3 (9%) stop at 75 or younger; 5 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 66 · Phase 3 18
First in 1992; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 81 is above the median of 52 across 168 interventional studies indexed under Thrombocythemia, Essential.
Median enrollment 45 across the 120 interventional studies, 592 across the 13 observational. Of the 113 that completed or were terminated, 36 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 149 have an industry lead sponsor. The 10 most frequent:
This study is registered under Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA), one of the names counted as Merck & Co., Inc. Under that name alone:
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) is the lead sponsor of 5 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Merck & Co., Inc has 5 studies filed under Thrombocythemia, Essential — fewer than ten, so there is no comparison to draw.
10 of the studies in Thrombocythemia, Essential with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06079879Phase 3Merck Sharp & Dohme LLCA Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) | 2027-07-14 |
| NCT06456346Phase 3Merck Sharp & Dohme LLCBomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) | 2027-09-28 |
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 10 to your calendar (.ics) → With an account.
Among the 149 studies in Thrombocythemia, Essential with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label extension study to assess the long-term safety and efficacy of bomedemstat administered orally once daily in participants with a Myeloproliferative Neoplasm (MPN) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies').
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion Criteria include, but are not limited to:
Exclusion Criteria:
Exclusion Criteria include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive bomedemstat via oral capsule daily for 169 days with additional treatment continuing in patients deriving clinical benefit.
Drug: Bomedemstat
Capsule (oral)
Also known as: IMG-7289, MK-3543
Percentage of Participants Who Experience an Adverse Event (AE)
An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who experienced an AE is presented.
Time frame: Up to ~32 months
Percentage of Participants Who Discontinue Study Intervention Due to an AE
An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study intervention due to an AE is presented.
Time frame: Up to ~32 months
Mean Spleen Volume Reduction Based on Spleen Volume Measured by MRI in Participants With MF.
Mean Spleen volume reduction (mL) in participants with MF as measured by central laboratory imaging analysis of MRI (or CT where applicable) approximately every 48 weeks. Per protocol only participants with MF were analyzed for this outcome measure. The change in spleen volume from baseline is presented.
Time frame: Baseline and Days 169, 339, 509, 679, 849 and 924
Percentage of Participants With ET Who Achieve a Reduction of Platelet Counts to <= 400 K/uL (400 x 10^9/L) in the Absence of New Thromboembolic Events
Blood samples were taken at designated time points to determine platelet count. Percentage of participants with ET who achieve a reduction of platelet counts to \<= 400 K/uL (400 x 10\^9/L) in the absence of new thromboembolic events is presented.
Time frame: Baseline and Days 29, 57, 85, 113, 141, 169, 198, 226, 254, 282, 310, 338, 367, 395, 423, 451, 479, 507, 536, 564, 592, 620, and 648
Participants with Myeloproliferative Neoplasms (MPNs) who participated in a prior bomedemstat study such as, but not limited to, IMG-7289-CTP-102/MK-3543-002 (NCT03136185) and IMG-7289-CTP-201/MK-3543-003 (NCT04254978) (referred to hereafter as 'feeder studies') were included in the recruitment.
| Milestone | Essential Thrombocythemia (ET) | Myelofibrosis (MF) |
|---|---|---|
| Started | 52 | 29 |
| Completed | 0 | 0 |
| Not completed | 52 | 29 |
| Withdrew: Adverse event | 6 | 3 |
| Withdrew: Death | 2 | 0 |
| Withdrew: Disease progression | 1 | 2 |
| Withdrew: Physician decision | 1 | 2 |
| Withdrew: Sponsor decision | 11 | 9 |
| Withdrew: Transferred to extension study mk-3543-017 (nct06351631) | 29 | 7 |
| Withdrew: Subject decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 6 |
An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who experienced an AE is presented.
| Percentage of Participants | Essential Thrombocythemia (ET) | Myelofibrosis (MF) |
|---|---|---|
| Percentage of Participants Who Experience an Adverse Event (AE) | 98.1 | 100.0 |
An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any clinically significant abnormalities in vital signs and lab values, untoward signs or symptoms experienced by the participant from the time of first dose with bomedemstat under this protocol until completion of the study. The percentage of participants who discontinued study intervention due to an AE is presented.
| Percentage of Participants | Essential Thrombocythemia (ET) | Myelofibrosis (MF) |
|---|---|---|
| Percentage of Participants Who Discontinue Study Intervention Due to an AE | 15.4 | 10.3 |
Mean Spleen volume reduction (mL) in participants with MF as measured by central laboratory imaging analysis of MRI (or CT where applicable) approximately every 48 weeks. Per protocol only participants with MF were analyzed for this outcome measure. The change in spleen volume from baseline is presented.
| mL | Essential Thrombocythemia (ET) | Myelofibrosis (MF) |
|---|---|---|
| Day 169 | — | -101.570 ± 92.6876 |
| Day 339 | — | -67.645 ± 249.0079 |
| Day 509 | — | -5.920 ± 143.1692 |
| Day 679 | — | -61.000 ± 396.2520 |
| Day 849 | — | -38.840 ± NA |
| Day 924 | — | 80.575 ± 10.3308 |
Blood samples were taken at designated time points to determine platelet count. Percentage of participants with ET who achieve a reduction of platelet counts to \<= 400 K/uL (400 x 10\^9/L) in the absence of new thromboembolic events is presented.
| Percentage of participants | Essential Thrombocythemia (ET) | Myelofibrosis (MF) |
|---|---|---|
| Day 29 | 77.1 (62.7 to 88.0) | — |
| Day 57 | 72.9 (58.2 to 84.7) | — |
| Day 85 | 72.0 (57.5 to 83.8) | — |
| Day 113 | 78.4 (64.7 to 88.7) | — |
| Day 141 | 91.8 (80.4 to 97.7) | — |
| Day 169 | 89.4 (76.9 to 96.5) | — |
| Day 198 | 86.7 (73.2 to 94.9) | — |
| Day 226 | 81.8 (67.3 to 91.8) | — |
| Day 254 | 79.5 (64.7 to 90.2) | — |
| Day 282 | 75.0 (59.7 to 86.8) | — |
| Day 310 | 81.4 (66.6 to 91.6) | — |
| Day 338 | 83.7 (69.3 to 93.2) | — |
| Day 367 | 76.2 (60.5 to 87.9) | — |
| Day 395 | 78.0 (62.4 to 89.4) | — |
| Day 423 | 80.0 (64.4 to 90.9) | — |
| Day 451 | 82.1 (66.5 to 92.5) | — |
| Day 479 | 75.7 (58.8 to 88.2) | — |
| Day 507 | 96.2 (80.4 to 99.9) | — |
| Day 536 | 94.7 (74.0 to 99.9) | — |
| Day 564 | 86.7 (59.5 to 98.3) | — |
| Day 592 | 72.7 (39.0 to 94.0) | — |
| Day 620 | 85.7 (42.1 to 99.6) | — |
| Day 648 | 83.3 (35.9 to 99.6) | — |
Collected over Death and adverse events up to ~32 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Essential Thrombocythemia (ET) | 2/52 (3.8%) | 19/52 (36.5%) | 45/52 (86.5%) |
| Myelofibrosis (MF) | 0/29 (0%) | 12/29 (41.4%) | 28/29 (96.6%) |
| Event | Essential Thrombocythemia (ET) | Myelofibrosis (MF) |
|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/52 | 2/29 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 0/52 | 2/29 |
| PneumoniaInfections and infestations | 3/52 | 1/29 |
| Skin lacerationInjury, poisoning and procedural complications | 2/52 | 0/29 |
| Acute kidney injuryRenal and urinary disorders | 2/52 | 0/29 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/52 | 1/29 |
| Cardiac failure congestiveCardiac disorders | 0/52 | 1/29 |
| Supraventricular tachycardiaCardiac disorders | 0/52 | 1/29 |
| Food poisoningGastrointestinal disorders | 0/52 | 1/29 |
| Gingival bleedingGastrointestinal disorders | 0/52 | 1/29 |
| Event | Essential Thrombocythemia (ET) | Myelofibrosis (MF) |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 15/52 | 14/29 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/52 | 12/29 |
| COVID-19Infections and infestations | 6/52 | 11/29 |
| AnaemiaBlood and lymphatic system disorders | 10/52 | 7/29 |
| DiarrhoeaGastrointestinal disorders | 5/52 | 7/29 |
| Gingival bleedingGastrointestinal disorders | 3/52 | 7/29 |
| ContusionInjury, poisoning and procedural complications | 4/52 | 6/29 |
| Bone painMusculoskeletal and connective tissue disorders | 0/52 | 6/29 |
| Rectal haemorrhageGastrointestinal disorders | 0/52 | 5/29 |
| DizzinessNervous system disorders | 8/52 | 4/29 |
| Age, Continuous(Years) | Essential Thrombocythemia (ET) | Myelofibrosis (MF) | Total |
|---|---|---|---|
| Mean | 65.8 ± 11.01 | 65.3 ± 9.68 | 65.6 ± 10.49 |
| Sex: Female, Male(Participants) | Essential Thrombocythemia (ET) | Myelofibrosis (MF) | Total |
|---|---|---|---|
| Female | 29 | 14 | 43 |
| Male | 23 | 15 | 38 |
| Ethnicity (NIH/OMB)(Participants) | Essential Thrombocythemia (ET) | Myelofibrosis (MF) | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 2 |
| Not Hispanic or Latino | 51 | 28 | 79 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Essential Thrombocythemia (ET) | Myelofibrosis (MF) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 14 | 15 | 29 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 1 | 4 |
| White | 35 | 13 | 48 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Baseline Spleen Volume by Magnetic resonance imaging/computerized tomography (MRI/CT) in mL(mL) | Essential Thrombocythemia (ET) | Myelofibrosis (MF) | Total |
|---|---|---|---|
| Median | — | 835.21 (98.88 to 3085.92) | 835.21 (98.88 to 3085.92) |
| Baseline Platelet Counts in thousands per microliter (10^3 cells/μL)(10^3 cells/μL) | Essential Thrombocythemia (ET) | Myelofibrosis (MF) | Total |
|---|---|---|---|
| Mean | 380.4 ± 207.44 | 190.5 ± 209.64 | 312.4 ± 226.29 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Dec 2021 to primary completion in Aug 2024, 32 months.
Results were first posted in Sep 2025, 1 year 1 month after primary completion.
Of 27 phase 2 interventional studies under Thrombocythemia, Essential, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 141. This study's 32 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bomedemstat
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) →